Prometheon Pharma Completes Pilot Study of Insulin Patch in Mini-Pigs

Prometheon Pharma Completes Pilot Study of Insulin Patch in Mini-Pigs

Prometheon has completed both privately funded and industry-sponsored large animal pilot studies of their needle-free insulin TruePatch. Early results of testing completed in August 2016 had already confirmed that Prometheon's extended-wear insulin patch works to lower blood glucose levels in a type 1 diabetic mini-pig model. These studies compared patch vs. subcutaneous needle injection delivery of the long-acting insulin analogue called glargine (LANTUS®, BASALIN®). Glargine for administration by injection will soon be available as a biosimilar from several other global generics manufacturers. Similar studies with other generic and modified insulins will identify the ideal insulins to use in both long-acting (basal) and rapid-acting (bolus) insulin patches, as well as address the need for heat-resistant patches for use in warm weather climates or low-resource settings where refrigeration is not available for retail distribution or home storage. 

Follow us on Twitter (#PatchOnPig) and Face Book

Read More

Prometheon Featured on CNBC's Fast Money with Melissa Lee

Prometheon Featured on CNBC's Fast Money with Melissa Lee

Devon Grimme (Director, Business Development) was featured live on CNBC's Fast Money with Melissa Lee on Tuesday, May 5, 2015. He shared his vision of how Prometheon's platform technology has the potential to shape the future of drug delivery. The broadcast was done on location at the eMerge Americas 2015 innovation conference, with Armando Perez (Pitbull) giving a keynote address in the background. 

See the video here

Read More

Prometheon Wins Global MIT Business Plan Competition

MIT-CHIEF is the largest China-focused event in the 150+ years of MIT's history. The MIT-CHIEF "Pitch to China" Business Plan Contest brings together hundreds of teams representing renowned institutions across the United States and China. This year, there were 200+ applicants from around the world. 52 teams reached the semi-finals across 5 different tracks. The 6 Finalists were selected by a panel of 50 experienced judges from the US and China. Despite fierce competition from other contestants including MIT and Harvard, Devon Grimmé (Director, Business Development) and Dr. Stephen Hsu (CEO/CSO) led Prometheon to the Grand Prize (1st Place) in an exciting Finale. 

Read the article here 

Read More

Prometheon's CEO/CSO Delivers Oral Presentation at the European Society for Paediatric Endocrinology Meeting (Dublin)


Dr.Stephen Hsu (CEO/CSO) presented on Prometheon R&D team's history-making studies of an optimized TopiconENDO™ human growth hormone patch formulation for needle-free extended-wear hormone replacement therapy in children and adults. He delivered his oral presentation at Europe's most prestigious international gathering of pediatric endocrinologists and scientists--the 53rd Annual ESPE Meeting (Dublin, Ireland). He has been invited to serve as an abstract reviewer for the 54th Annual ESPE Meeting (Barcelona, Spain).